ZyVersa is advancing a pipeline of first-in-class drug candidates built around two proprietary technologies. - Inflammasome ASC Inhibitor IC 100 designed to attenuate initiation and perpetuation of disease-causing inflammation; lead indication: obesity with metabolic complications (e.g.,
Strokes affect 795,000 people annually in the US. Obesity, a top risk factor for strokes, is associated with around one out of five strokes. Cardiac complications following a stroke are a leading cause of mortality and morbidity, second only to acute neurological injury.
KEY BUSINESS HIGHLIGHTS Phase 2a clinical trial for Cholesterol Efflux Mediator™ VAR 200 in patients with diabetic kidney disease expected to begin Q1-2025. New Obesity, Metabolic & Inflammatory Disease Scientific Advisory Board (SAB) was formed in October 2024 to support development of
During obesity, inflammasome-driven inflammation results in significant loss of pancreatic islet beta cell mass, severely impairing the insulin secreting capacity of the remaining beta cells. Preserving pancreatic islet beta cell function is key to prevention of insulin resistance and development
Obesity, due to its associated chronic, systemic inflammation, increases the risk for metabolic diseases, atherosclerosis, various malignant tumors, and numerous immune-mediated disorders. With weight loss, less inflammation is expected, but adipose tissue inflammation can persist long after weight
Recent evidence links obesity-driven inflammation to diminished brain health and neurodegenerative diseases such as Alzheimer’s and Parkinson’s diseases The newly published data show that obesity leads to progressive brain inflammation in a mouse model, and that the proinflammatory processes worsen
Lead indication for ZyVersa’s Inflammasome ASC Inhibitor IC 100 is obesity with metabolic complications. WESTON, Fla., Oct. 17, 2024 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for
Lead indication for ZyVersa’s Inflammasome ASC Inhibitor IC 100 is obesity with metabolic complications. WESTON, Fla., Oct. 15, 2024 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for
New Scientific Advisory Board (SAB) comprised of five leading experts in the areas of obesity and metabolic diseases, and four leading inflammasome experts and inventors of IC 100 from University of Miami Miller School of Medicine who have provided ongoing scientific advisory support for IC 100
KEY HIGHLIGHTS Phase 2a clinical trial for Cholesterol Efflux Mediator™ VAR 200 in patients with diabetic kidney disease on track to begin H2-2024. Obesity with related metabolic complications selected as lead indication for Inflammasome ASC Inhibitor IC 100.
